Tolerance & biocompatibility
Irritation and cytotoxicity assessments support the manufacturer’s tolerance evaluation.
ISO 10993-10 / ISO 10993-5 · as cited by the manufacturer
About IONALYS
A new approach to nasal allergy care
IONALYS is a French nasal spray developed for adults aged 18 and over with seasonal or year-round allergic rhinitis. Its ADW S-100 ionised water technology is designed to help detach allergens and particles so they can be rinsed away from the nasal passages. With a 100% natural formula and no traditional preservatives, it offers a physical approach to the prevention and relief of nasal allergy symptoms. Developed by M. Richard Laboratories, part of P&B Group, IONALYS brings this technology to a compact, airless 20 ml spray.
IONALYS in motion
European medical device
Class IIa
CE marked under EU MDR
Regulation (EU) 2017/745
0459
GMED Notified body 0459
Certified 15 October 2025
Product certificationAn animated studio presentation of the IONALYS nasal spray and carton, gently turning and gliding in a bright white setting with teal and green accents.
Laboratoires M. Richard
French expertise.
From research
to production.
Based in Saulce-sur-Rhône, near Montélimar, Laboratoires M. Richard is the French pharmaceutical manufacturer behind IONALYS. Part of P&B Group’s Health Division, it brings together research, regulatory expertise, manufacturing and packaging for medicines, medical devices and food supplements.
Scientific rigour guides every stage, from raw-material testing to finished-product quality control. With pharmaceutical GMP, ISO 13485 and HACCP credentials, the laboratory combines development expertise with industrial capability to support partners from formulation to commercial production.
IONALYS / The water technology
Active water. Seven minerals.
Advanced Water S-100®
The process
01
Purified source water
The starting point
of the formulation.
02
Seven minerals
NaMgCaSiPKCl
03
Electrolysis
The ADW S-100® process
creates active ionised water.
The formula
Active ionised water
Stable alkaline water
containing hydroxide ions.
Natural formula
Water and minerals.
No traditional preservatives.
Self-preserving
Microbiological preservation
assessed by challenge tests.
Manufacturer’s technology and formulation information ISO 11930 challenge tests
IONALYS / How it works
Ionic action.
Mechanical
rinsing.
ADW S-100® combines ionic interaction with mechanical rinsing to help loosen particles and support their removal from the nasal passages.
Ionic repulsion and charge neutralisation help limit particle adhesion, followed by removal through mechanical rinsing.
Nasal surface Schematic view
Surface particlesActive ionised water
Illustration of the manufacturer-described mechanism.
IONALYS / Evidence
The evidence
behind IONALYS.
Clinical results for ADW S-100®, supported by a separate programme of tolerance and biocompatibility testing.
Human clinical studyReported results
−41.7%
Runny nose
Rhinorrhoea
−37.5%
Sneezing
Allergic-rhinitis symptom
Reported symptom reductions after 14 days.¹
Study context
- Users¹
- 96
- Days of use
- 14
Randomised, double-blind, placebo-controlled
SPRA clinical trial · 2023
Laboratory / Tolerance assessment
- In vitro / Epithelix, 2024
- Increased mucin secretion and ciliary activity reported in a nasal epithelial model.
- Biocompatibility testing
- Irritation and cytotoxicity tests support the manufacturer’s tolerance assessment.
IONALYS / Scientific validation
Studied at the
nasal surface.
From the epithelial model to formulation testing: a closer look at the evidence supporting ADW S-100®.
Nasal epitheliumIllustrative model
Cilia and mucus work together to clear the nose.
Epithelix · 2024In vitro
- Epithelial integrity
- Integrity maintained in the nasal cell model.
- Mucus function
- Increased mucin secretion and ciliary activity.
- Gap closure
- Faster closure reported in a laboratory scratch assay.
Original assay images 30 hours
Blue overlay: remaining gap. Cropped from the manufacturer’s study extract.
Formulation preservation
Microbiological preservation assessed through challenge testing, according to the manufacturer.
ISO 11930 · challenge test
Broader technology researchPublished laboratory studies
2021 / Skin cellsCeramide synthesis 2024 / Skin cellsOxidative stress 2022 / In vitroVirucidal activityIONALYS / A different approach
What makes
IONALYS different?
A familiar rinsing action.
An added ionic dimension.
01 Conventional isotonic saline
Mechanical rinsing
Saline flow washes the nasal passages, helping remove mucus, allergens and particles.
02 IONALYS / ADW S-100®
Ionic action + rinsing
Active ionised water is designed to help detach particles through repulsion and charge neutralisation, before rinsing them away.
Inside
IONALYS
Active
ionised water
Seven-mineral
formulation
No traditional
preservatives
IONALYS / Who it is for
Designed for adults
living with
nasal allergies.
For seasonal or year-round allergic rhinitis, linked to common allergy triggers.
- Pollen
- Dust mites
- Animal allergens
20 ml
Compact airless nasal spray
Adults 18+
Intended use and format: manufacturer’s product documentation.
IONALYS / How to use
Three sprays.
A simple routine.
- Sprays in
each nostril - 3
- Times
per day - 3–4
- Days
of use - 14
Illustrative product animation
The collaboration
Shortcut MEA × P&B Group / Laboratoires M. Richard
One collaboration.
Ten markets.
Shortcut MEA supports the export development of IONALYS / ADW S-100® across selected markets in the Middle East and Africa.
Our mandate
- 01
Develop the markets.
Prioritise opportunities and shape the route to market.
- 02
Connect the right partners.
Identify, assess and engage distributors, then support commercial alignment.
- 03
Support launch & growth.
Coordinate market entry and launch planning with P&B / Laboratoires M. Richard and appointed local partners.
Countries covered
- North Africa
- Morocco · Tunisia · Libya · Egypt
- Gulf
- Saudi Arabia · UAE · Kuwait · Qatar · Bahrain
- Southern Africa
- South Africa
Market focus Kingdom of Saudi Arabia
SaudiArabia.
The market opportunity
for IONALYS.
Saudi Arabia / Allergic rhinitis
A common condition.
A clear need.
Published Saudi evidence shows a substantial burden of nasal allergy, with higher pooled estimates in adults.
Evidence, before opportunity.
Approximately 1 in 5
21.2%1
Pooled allergic rhinitis prevalence
across the included Saudi populations
All ages · 95% CI 12.8–33.1%
The impact of symptoms
More than
occasional discomfort.
61.5%2
reported moderateto severe symptoms
- Continuous symptoms
- 53.4%
- No medication use
- 43.5%
2024 ARSIA online survey · 262 respondents with self-reported AR; 95.4% aged 18+. These are proportions among respondents with AR, not population prevalence.
Saudi evidence & sources 10 publications · prevalence, symptoms & care
The evidence in context.
A focused review of Saudi publications, checked 23 October 2026. Local surveys, pooled estimates, symptom screens and reports of a previous diagnosis measure different things. They should not be combined into a trend or extrapolated to a national patient count.
Aburiziza et al. — Saudi systematic review & meta-analysis
16 articles; 31,990 participants overall. The prevalence analysis pooled 15 studies: 21.2% (95% CI 12.8–33.1%; I² 99.74%). Adult subgroup: 31.1% (11.6–60.9%; 5 studies). Urban and rural subgroup estimates were 38.4% and 13.0%; they are not adjusted comparisons.
Reported pooled triggers included perfume 36.8%, dust 27.3%, air conditioning 23.4% and weather/temperature changes 17.8%. Pooled symptom estimates included sneezing 24.6%, runny nose 22.2% and congestion 22.0%. Study populations and denominators vary. Validated-tool studies estimated 16.2%, versus 35.1% for self-developed tools, illustrating the importance of measurement.
Mixed ages and methods, with very high between-study heterogeneity. The pooled figure is not a representative national survey.
Journal of Asthma and Allergy · DOI 10.2147/JAA.S391142 ↗Mohammad et al. — ARSIA survey across Saudi Arabia
262 respondents who already reported AR; convenience sample, February 2024. 61.5% reported moderate/severe symptoms; 53.4% continuous symptoms; 43.5% no medication. Antiallergic spray alone: 23.3%; antihistamine alone: 19.1%; both: 14.1%. The sample included 250 adults and 12 people under 18.
Describes people with self-reported AR; it cannot estimate AR prevalence in the Saudi population or establish why people did not use medication.
Cureus · DOI 10.7759/cureus.76423 ↗Almatroudi et al. — Respiratory allergies in Qassim
13.5% reported diagnosed allergic rhinitis in an online survey of 850 residents aged 18+, September–December 2020. Any respiratory allergy was reported by 28.8%; that broader figure includes conditions other than AR.
Regional, self-reported diagnosis; internet survey recruitment limits generalisability.
PLOS ONE · DOI 10.1371/journal.pone.0253558 ↗Al-Ghamdi — Adult allergic rhinitis in Aseer
30.2% had symptoms used as a proxy for AR in the preceding 12 months (95% CI 27.3–33.2%); 290 of 960 adults aged 20+, recruited at five primary healthcare centres. An adapted Arabic ISAAC questionnaire was used.
Regional healthcare-attendee sample. The figure shown follows the abstract and results; the discussion contains an inconsistent 36.1% value.
World Family Medicine · 2020;18(5):20–25 ↗El-Gamal et al. — Prevalence & determinants in Jeddah
37% of 650 respondents were reported to have AR in this cross-sectional questionnaire study. Nasal blockage, sneezing, runny nose, headache and nasal itching were common symptoms; the study also examined quality of life.
A local survey estimate; it should not be treated as national prevalence.
Medical Science · 2023;27:e262ms3083 ↗Alqarni et al. — Prevalence, knowledge & practices in Bisha
54.3% (219/403) were reported to have AR among adults aged 18+, recruited voluntarily through social media from November 2024 to 1 January 2025. Adequate knowledge was reported for 78.4%; poor/inappropriate practices for 54.1% of the full sample.
A voluntary local online sample; the estimate is not nationally representative.
IJMDC · DOI 10.24911/IJMDC.51-1736007198 ↗Ali — Smoking & allergic rhinitis
24.9% (71/285 adults) reported ever receiving an AR diagnosis from a medical professional. Survey responses were collected in Al-Kharj between May 2024 and March 2025.
A local, retrospective self-report of diagnosis; this differs from current symptom prevalence.
Asian Journal of Pharmaceutics · DOI 10.22377/ajp.v19i2.6464 ↗Munhish et al. — Symptoms & risk factors in the southwest
Online questionnaire study of 400 adults. Reported symptoms included sneezing 71.8%, runny nose 69.0% and blocked nose 69.2%. House dust, perfumes and dust mites were reported triggers.
These are individual symptom frequencies in the study sample, not a single confirmed AR prevalence estimate.
IJMDC · DOI 10.24911/IJMDC.51-1762083481 ↗Almehizia et al. — Disease characteristics & coping measures
Of 3,458 online respondents, 2,849 (82.4%) reported at least one specified nasal/ocular symptom without cold or flu. Among the symptomatic group, dust was reported as the leading trigger (74%); 46% had a persistent pattern.
Convenience recruitment and a broad symptom screen; 82.4% is not a clinically confirmed national prevalence estimate. The paper contains inconsistent moderate/severe symptom figures, so that comparison is not used here.
PLOS ONE · DOI 10.1371/journal.pone.0217182 ↗Alnahas et al. — National school survey
Multistage school sampling across 20 health regions. In the reported analyses, current rhinitis symptoms affected 14.3% of children aged 6–7 and 30.3% of adolescents aged 13–14; current rhinoconjunctivitis affected 5.6% and 14.0%, respectively. The abstract reports 3,614 children and 4,068 adolescents.
Different symptom definitions yield different estimates. Included for epidemiological context only: IONALYS is intended for adults aged 18+.
World Allergy Organization Journal · 2023;16:100824 ↗
Research interpretation: the studies support a meaningful adult nasal-allergy care need. They do not establish demand for a specific brand, a national patient total, or IONALYS treatment effects. Pregnancy rhinitis and sinusitis are separate conditions and are excluded from these prevalence figures.
Saudi Arabia / Market size & growth
Nasal care.
A growing market.
Saudi nasal sprays
Prescription + OTC
Historical estimates · 2021–2024Publisher forecast · 2025–2034
Study figures & source Annual values · 2021–2034
The study behind
the curve.
Figures are reproduced from the supplied Global Market Insights workbook, Excel - Nasal Spray Market Report, 2025 - 2034 (1)(1).xlsx, “Middle East and Africa” tab, Saudi Arabia country-value row 15. The accompanying report identifies 2024 as its base year and 2025–2034 as its forecast period.
The 2026 value is from H15, the 2034 value from P15, and the published CAGR from Q15. Values are displayed to one decimal place. The curve uses every annual workbook value, with a zero baseline.
This is the total nasal spray category across prescription and OTC products. It is broader than the IONALYS addressable segment.
| Year | Market value | Study classification |
|---|---|---|
| 2021 | 180.7 | Historical estimate |
| 2022 | 190.1 | Historical estimate |
| 2023 | 200.2 | Historical estimate |
| 2024 | 211.3 | Historical estimate |
| 2025 | 223.5 | Publisher forecast |
| 2026 | 236.6 | Publisher forecast |
| 2027 | 251.4 | Publisher forecast |
| 2028 | 267.7 | Publisher forecast |
| 2029 | 286.3 | Publisher forecast |
| 2030 | 307.5 | Publisher forecast |
| 2031 | 330.8 | Publisher forecast |
| 2032 | 356.5 | Publisher forecast |
| 2033 | 384.5 | Publisher forecast |
| 2034 | 415.8 | Publisher forecast |
Saudi Arabia / Market fit
Where IONALYS fits.
2026 publisher forecast
Share of total nasal spray market value
01By application
45.6%
USD 107.8 million
Rhinitis
Allergic & non-allergic rhinitis
IONALYS focuses on allergic rhinitis.
02By patient type
64.3%
USD 152.2 million
Adults
Adult nasal spray market
IONALYS is intended for adults aged 18+.
03By access type
44.7%
USD 105.6 million
OTC
Over-the-counter nasal sprays
A pharmacy self-care opportunity to assess.
A focused proposition
for adult allergy care.
Advanced ADW S-100 Water TechnologyStudy data & calculation Segment values, definitions & sources
Three perspectives.
One market.
The supplied study segments the market separately by application, patient type and access type. The figures shown are independent shares, calculated as each segment’s forecast 2026 revenue divided by the total Saudi nasal spray forecast of USD 236.6 million.
The rhinitis category includes both allergic and non-allergic rhinitis. The manufacturer describes IONALYS for allergic rhinitis in adults aged 18 and over. The OTC figure describes the study’s market category; it does not establish IONALYS’s Saudi classification.
These shares are not added or multiplied to estimate a combined segment. The study does not provide the overlap of adult, allergic-rhinitis and OTC sales.
| Study segment | Value | Share | Cell |
|---|---|---|---|
| Allergic and non-allergic rhinitis | 107.8 | 45.6% | H175 |
| Adults | 152.2 | 64.3% | H183 |
| Over the counter (OTC) | 105.6 | 44.7% | H192 |
Source: Excel - Nasal Spray Market Report, 2025 - 2034 (1)(1).xlsx, “Middle East and Africa” tab. Segment cells shown above; total in H15. Percentages are calculated from the full-precision source values and rounded to one decimal place.
Saudi Arabia / Route to market
Pharmacies at the heart
of the opportunity.
A retail and digital route
to reach Saudi consumers.
Where nasal sprays are sold
2026 publisher forecast · Share of market value
Saudi Arabia's total nasal spray market by distribution channel. Retail pharmacies: 46.8%, USD 110.8 million. Online pharmacies: 15.3%, USD 36.2 million. Hospital pharmacies: 37.8%, USD 89.5 million. Percentages are rounded; the chart uses the full-precision source values.
Retail pharmacies
USD 110.8 million
Online pharmacies
USD 36.2 million
Hospital pharmacies
USD 89.5 million
62.2%
Retail + online pharmaciesShare of total market value
Launch recommendation
Retail reach. Digital convenience.
A pharmacy-led launch, supported by online availability.Study data & calculation Channel values, scope & sources
Three channels.
One market.
The chart uses the study’s 2026 Saudi distribution-channel forecasts. Each share is calculated by dividing channel revenue by the total forecast of USD 236.6 million. Segment widths use full-precision values.
Retail and online pharmacies are distinct channels in this breakdown. Together they represent USD 147.1 million, or 62.2% of total market value: (H205 + H207) ÷ H208 × 100.
The scope includes all nasal sprays, both prescription and OTC. This is a channel view, not an estimate of IONALYS sales or its addressable segment. The launch recommendation is our interpretation of the study; local product classification and registration remain to be confirmed.
| Study channel | Value | Share | Cell |
|---|---|---|---|
| Retail pharmacies | 110.8 | 46.8% | H205 |
| Online pharmacies | 36.2 | 15.3% | H207 |
| Hospital pharmacies | 89.5 | 37.8% | H206 |
Source: Excel - Nasal Spray Market Report, 2025 - 2034 (1)(1).xlsx, “Middle East and Africa” tab. Segment cells shown above; total in H208. Percentages are calculated from full-precision source values and rounded to one decimal place. The bar is reordered to place retail and online pharmacies together.
Saudi Arabia / The Nahdi opportunity
A new chapter
in nasal allergy care.
A partnership proposal for Nahdi.
Nahdi / The partner fit
Why Nahdi.
Reach. Distribution. Expertise.
A platform to introduce and build brands.
The reach to launch.
The capability to build.
1,217
Pharmacy reach
Reported pharmacy network
30.2%
Digital access
Online share of total revenue
18.9%
Own-brand capability
Private-label share of total revenue
Company-reported indicators · H1 2026
01 / Distribution capability
IMDAD.
The infrastructure to deliver.
Automated fulfilment and temperature-controlled handling in Jeddah, supporting Nahdi’s pharmacy and online delivery network.
222m
units delivered by Nahdi in 2024
Company-reported volume · all categories
02 / Commercial expertise
Pharmacy knowledge.
Brand-building experience.
Pharmacy retail, digital engagement and private-label development, with 12 local medicine manufacturing partners in 2025.
39+
years of pharmacy experience
As described in Nahdi’s company profile
03 / International brand experience
A record of bringing
brands to market.
Weight management
GoFigure®
Launch confirmed · January 2023
OptiBiotix confirmed launch through Nahdi after Saudi registration.
Source 05Weight management
SlimBiome® Medical
Agreement announced · December 2021
Included in OptiBiotix’s exclusive Saudi supply agreement with Nahdi.
Source 06Beauty & personal care
Joelle Paris
Appointment announced · February 2018
Nahdi appointed exclusive distributor in Saudi Arabia.
Source 07Selected announced distribution partnerships · Historical examples, with announcement or launch dates shown.
The fit for IONALYS
One technology.
Two ways to grow together.
Sources & scope Figures, capabilities & brand relationships
The evidence.
The proposed fit.
The three headline figures are reported by Nahdi for H1 2026. The pharmacy count is the company’s reported retail footprint; no Saudi-only country split or IONALYS listing commitment is inferred. The online and private-label shares concern total company revenue, not nasal-care category sales or margins.
The 222 million units are Nahdi’s reported deliveries in 2024 across its business, not IMDAD’s stated capacity or a measure of independent pharmacies served. The 39+ years description is from Nahdi’s company profile; the 12 local medicine manufacturing partnerships relate to 2025.
GoFigure, SlimBiome® Medical and Joelle Paris are dated examples of announced distributor relationships. GoFigure’s January 2023 launch is separately confirmed by its manufacturer. The 2021 SlimBiome® Medical agreement is not presented as proof of a subsequent launch. The historical announcements do not establish present exclusive rights, current sales volumes or a general wholesale network outside Nahdi.
Our interpretation is that retail reach, distribution infrastructure, pharmacy expertise and brand experience provide a basis to discuss original IONALYS distribution and a Nahdi own-brand extension. Commercial terms, the scope of distribution and local product registration remain to be agreed.
- 01 / Headline figuresH1 2026 earnings release ↗
Published 29 July 2026, page 3: 1,217-store footprint; online 30.2% and private label 18.9% of total revenue. Corroborated by the Q2 2026 factsheet ↗.
- 02 / Distribution scaleNahdi 2024 annual report ↗
Printed page 22 (PDF page 12) reports 222 million units delivered in 2024. This is a historical company delivery figure.
- 03 / IMDAD operationsSSI SCHAEFER’s Nahdi case study ↗
The automation supplier describes automated fulfilment, intelligent logistics software and temperature-controlled systems at IMDAD. Facility capacity figures are not used as actual deliveries.
- 04 / Expertise & partnershipsNahdi’s company profile & strategy ↗
Describes over 39 years of experience, pharmacy retail, omnichannel operations and private-label development. Its 2025 highlights identify partnerships with 12 local medicine manufacturers. The page contains differing distribution-centre counts, so no centre count is used. The pharmacy image is from Nahdi’s investor website ↗. Capabilities and brand examples checked 24 October 2026.
- 05 / GoFigure®Launch confirmed · January 2023 ↗
Exclusive distributor named by OptiBiotix in its 2022 results, published 28 June 2023.
- 06 / SlimBiome® MedicalAgreement announced · December 2021 ↗
A range named in the announced agreement; subsequent launch or current exclusivity is not inferred.
- 07 / Joelle ParisAppointment announced · February 2018 ↗
Historical appointment reported in an Arab News sponsored corporate announcement dated 27 February 2018. Nahdi Online listing ↗ also confirms the brand is retailed; it does not independently establish current exclusive rights.
Nahdi / The range opportunity
An established range.
A new technology to add.
Current offer
+ a proposed complement
Existing Nahdi products
Three listed formats
Hypertonic sea water
100ml
SAR 56.00
EUR 13.34USD 14.93
Hypertonic sea water
30ml
SAR 51.00
EUR 12.15USD 13.60
Saline nasal spray
15ml
SAR 39.00
EUR 9.29USD 10.40
The opportunity
Complement the range.
Expand the adult allergy proposition.
Product pages & positioning Prices, currency equivalents & source dates
Build on the offer.
Add a different technology.
This view covers the three Nahdi SKUs supplied for the proposal, rather than an exhaustive audit of Nahdi’s nasal-care assortment. Product titles, formats, pack images and listed prices are taken from the linked Saudi product pages. Prices were checked on 26 October 2026 and may change; multi-buy promotions are not incorporated.
EUR and USD figures convert the listed Saudi unit price; they are not retail prices in Europe or the United States. USD = SAR ÷ 3.75. EUR = USD ÷ 1.1193. Calculations use full precision, then round to two decimals. The ECB reference is dated 23 October 2026, the latest available at verification.
ECB · EUR 1 = USD 1.1193 ↗
Saudi Central Bank · SAR 3.75 per USD ↗
Nahdi already describes allergy-related congestion uses for its hypertonic products. The proposed complement is the manufacturer-described ADW S-100® active-water technology and its adult allergic-rhinitis positioning. The slide does not claim that Nahdi has no allergy offer or establish a head-to-head efficacy ranking.
IONALYS is shown in its current packaging. A Nahdi own-brand version is a proposal requiring agreed artwork, product claims, commercial terms and local registration.
| Product / source | SAR | EUR | USD |
|---|---|---|---|
| Hypertonic sea water · 100 ml ↗SKU 101959771 | 56.00 | 13.34 | 14.93 |
| Hypertonic sea water · 30 ml ↗SKU 101959780 | 51.00 | 12.15 | 13.60 |
| Saline nasal spray · 15 ml ↗SKU 101959798 | 39.00 | 9.29 | 10.40 |
Proposed addition / manufacturer sourceM. Richard Laboratories / P&B Group ↗
Release dated 26 November 2025, pages 1–3. Describes a 20 ml ADW S-100® nasal spray for adult allergic-rhinitis symptoms and European Class IIa CE marking under MDR. European certification does not establish Saudi approval.
Nahdi / The partnership proposal
One technology.
Two ways to grow with Nahdi.
01
Branded distribution
Bring IONALYS
to Saudi Arabia.
Introduce the original brand through Nahdi’s pharmacies and online platform.
Shared technology
ADW S-100®Active ionised water02
Nahdi own brand
Create Nahdi’s
own version.
Develop a Nahdi-branded ADW S-100® version to complement its nasal-care range.
Proposed models for discussion. Final artwork, claims, local registration and commercial terms to agree.
Shape the partnership01 The IONALYS distribution model
Distribute IONALYS.
Build the brand in Saudi Arabia.
What Nahdi sells
The finished IONALYS product.
Original branding, ADW S-100® technology and the manufacturer-supported adult allergy-care positioning.
Nahdi’s proposed role
Develop the Saudi market.
Sell through Nahdi and other agreed pharmacy channels, with local market access, stock and activation led through the agreed operating structure.
Proposed partner support
Supply. Documentation. Coordination.
P&B / Laboratoires M. Richard: product supply, technical dossier and product-training content. SCMEA: commercial coordination.
The commercial logic
Revenue from branded
product sales.
Purchase finished IONALYS stock and distribute through the agreed Saudi channels.
To agree together
- Territory & distribution rights
- Supply price & volumes
- Launch commitments
02 The Nahdi own-brand model
Create Nahdi’s own version.
Built on ADW S-100®.
01 / Branding
Nahdi’s name and packaging.
Develop a Nahdi-branded version for the existing nasal-care range.
02 / Technology
The ADW S-100® technology.
Confirm specifications and supported claims with the manufacturer and through local registration.
03 / Partnership
Nahdi leads the brand.
Nahdi: positioning, artwork and activation. Manufacturer: feasibility, documentation and supply. SCMEA: coordination.
The commercial logic
Product sales under
the Nahdi brand.
Purchase a Nahdi-branded finished product under agreed development and supply terms.
- Nahdi presentation
- Manufacturer supply
- Nahdi retail & online
To agree together
- Product specification & claims
- Minimum order & lead times
- Pricing & supply terms
04 The margin dynamics
The value that
stays with Nahdi.
From the supplier’s premises to the Saudi shelf. How cost builds up — and who retains the gross profit.
First, build the landed cost of one unit.
EXW supply price
Agreed finished-product price at the supplier’s named premises.
Inbound logistics & import
Collection, freight, delivery, clearance and applicable import charges.
Landed cost
Cost of the unit at the agreed Saudi warehouse.
Include insurance if arranged, applicable duty and non-recoverable charges. Exclude recoverable import VAT. EXW is the supply price paid to the manufacturer, including its commercial return.
Model 01
IONALYS
distribution.
Price chain for sales to other pharmacies.
EXW
Agreed price for the finished IONALYS product.
Landed
costEXW plus inbound logistics and import charges.
Wholesale
priceNahdi’s selling price to other pharmacies.
RSP
The other pharmacy’s retail selling price.
Who retains the gross profit?
- Nahdi · distribution
- Net wholesale price − landed cost
- The other pharmacy · retail
- Net retail sales − wholesale purchase price
When IONALYS is sold through Nahdi’s own channels: Nahdi retains net retail sales minus landed cost. Internal transfers create no extra group profit.
Model 02
Nahdi
own brand.
Price chain through Nahdi pharmacies and online.
EXW
Agreed price for the finished Nahdi-branded product.
Landed
costEXW plus inbound logistics and import charges.
RSP
Nahdi’s retail selling price through its own channels.
Who retains the gross profit?
- Nahdi · own-brand retail
- Net retail sales − landed cost
The full landed-to-net-retail spread stays within Nahdi on its own-channel sales, before marketing and operating costs.
The manufacturer is paid through the agreed own-brand EXW supply price. The potential advantage comes from negotiated supply economics and ownership of the Nahdi brand.
Arrows show the commercial sequence. Spacing does not represent a price or margin.
A common price basis
Net selling price−Landed cost=Nahdi gross profit
RSP = retail selling price. All prices illustrated above exclude applicable VAT. Net selling prices reflect discounts, returns and agreed deductions. Use Nahdi’s wholesale price for external accounts, or its net retail sales for its own channels.
At a comparable net RSP, the agreed landed cost determines the gross profit retained on Nahdi’s own-channel sales. Marketing and operating costs then determine the contribution.
Cost definitions, channel economics & sources
EXW to landed cost
EXW means Ex Works at a named place under Incoterms® 2020. The supplier makes the finished product available there. The buyer generally arranges collection, loading, export formalities, transport and import clearance. Insurance is included in this cost build-up only if purchased; EXW does not itself require either party to insure.
The landed-cost boundary used here is delivery to the agreed Saudi warehouse. Include directly attributable inbound costs, applicable duties and non-recoverable taxes, after purchase discounts or rebates. Recoverable VAT is a cash-flow item rather than product cost. No tax, duty, currency conversion or supply-price rate has been assumed.
Price versus profit
RSP is the retail selling price. The diagram uses a VAT-exclusive basis. If a shelf price is VAT-inclusive, remove the applicable VAT before comparing it with costs. Net sales also reflect actual discounts, returns and deductions.
For external wholesale sales, Nahdi’s revenue ends at the net wholesale selling price; the independent retailer earns the subsequent retail spread. For sales through Nahdi’s own pharmacies or online channel, use net retail sales. Internal transfers do not add consolidated revenue or profit.
Comparing the models
The own-brand route illustrates sales through Nahdi’s own channels. It does not claim the branded model must use an external retailer: the visible own-channel note shows that Nahdi also retains the full landed-to-net-retail spread when retailing IONALYS itself. An own-brand sale to an external retailer would likewise leave that retailer its retail economics.
Both EXW prices are negotiated finished-product supply prices, not bare manufacturing costs. The manufacturer’s economics and any agreed technology, development, packaging or other supply charges still apply. There is no automatic higher margin or transfer of technology ownership. Any supply charges must be included once, in the agreed cost structure.
From gross profit to contribution
This is a simplified commercial product-margin bridge, before marketing, operating costs and other adjustments. Registration, artwork, development, storage, outbound fulfilment, stock provisions and other costs must be assessed and allocated under the agreed structure and accounting policy; they are not all automatically import costs.
The Nahdi pack is illustrative. Product specifications, claims, local registration and supply terms require agreement. Price levels and margin percentages will be developed later from agreed inputs.
Definition sources
ICC Academy · EXW responsibilities ↗
IFRS Foundation · IAS 2 overview ↗
AASB 102, paragraph 11 · Purchase-cost components ↗
The cost definitions are informed by these references. The channel routes and proposed margin allocation are our commercial illustration for discussion; they are not published Nahdi supply terms.
05 From ambition to activation
Building the
Saudi business.
Four growth drivers.
One coordinated commercial approach.
For IONALYS and the proposed Nahdi own-brand extension.
Pharmacist
education.Explain the technology, supported claims and the relevant adult customer.
Both modelsIn-store
visibility.Give IONALYS a clear role on shelf, alongside the proposed Nahdi range extension.
Both modelsDigital
activation.Connect product discovery, educational content and conversion through Nahdi Online.
Both modelsWider
distribution.Extend IONALYS into agreed Saudi pharmacy accounts, supported by dependable availability.
IONALYS distribution
Four complementary drivers, designed to work together.
Reliable supply supports every step.
06 The proposed partnership
A partnership
built to execute.
Three complementary roles.
One coordinated approach.
Proposed responsibilities for discussion.
P&B Group / Laboratoires M. Richard
Technology
& product.
- Product technology & technical documentation
- Manufacturing, quality & supply
- Own-brand feasibility & supported claims
Shortcut MEA
Commercial
coordination.
- Manufacturer interface
- Joint business planning
- Performance follow-up
Nahdi
Saudi market
development.
- Market access & local registration coordination
- Distribution, retail & digital activation
- Own-brand positioning
07 The next chapter
Confirm the direction.
Explore interest in both
business models.Align the commercial
framework.Distribution, own-brand development
and supply terms.Prepare for launch.
Product requirements, registration
and commercial readiness.
A Supporting detail
Behind the
proposition.
Product references, scientific evidence and the assumptions behind the Saudi opportunity.
01
Product & certification referencesFormat, European device status and source documents
↗02Scientific studiesProduct-specific evidence and wider technology research
↓03Saudi market dataAnnual study values, scope and source methodology
↗04Commercial assumptionsFive-year ambition, share basis and value-chain definitions
↗Product & certification references
IONALYS is presented in the supplied manufacturer documentation as an airless 20 ml nasal spray for adults with allergic rhinitis, based on ADW S-100 ionised water technology.
- European device status
- Class IIa medical device, CE marked under Regulation (EU) 2017/745.
- Notified body
- GMED · 0459. Certification dated 15 October 2025 in the manufacturer release.
- Saudi market access
- Local classification, registration arrangements and approved claims remain to be confirmed. European certification does not establish Saudi authorization.
- Nahdi own brand
- Illustrative development proposal. Final specifications, artwork, supported claims, local registration and supply terms require agreement.
Manufacturer release & CE-marking summary ↗Product certification in the presentation ↑Manufacturer credentials & published sources ↑
Saudi market data & methodology
Source: the supplied Global Market Insights workbook, Excel - Nasal Spray Market Report, 2025 - 2034 (1)(1).xlsx, “Middle East and Africa” sheet, Saudi country-value row 15. Base year: 2024. Publisher forecast period: 2025–2034.
The category includes prescription and OTC nasal sprays. It is broader than the IONALYS addressable segment. Values are shown to one decimal place from the full-precision supplied workbook. This presentation uses that supplied edition.
| Year | Market value | Study classification |
|---|---|---|
| 2021 | 180.7 | Historical estimate |
| 2022 | 190.1 | Historical estimate |
| 2023 | 200.2 | Historical estimate |
| 2024 | 211.3 | Historical estimate |
| 2025 | 223.5 | Publisher forecast |
| 2026 | 236.6 | Publisher forecast |
| 2027 | 251.4 | Publisher forecast |
| 2028 | 267.7 | Publisher forecast |
| 2029 | 286.3 | Publisher forecast |
| 2030 | 307.5 | Publisher forecast |
| 2031 | 330.8 | Publisher forecast |
| 2032 | 356.5 | Publisher forecast |
| 2033 | 384.5 | Publisher forecast |
| 2034 | 415.8 | Publisher forecast |
Rhinitis publications & prevalence sources ↑Segment definitions & calculations ↑Distribution-channel values & calculations ↑
Commercial ambition & assumptions
The combined ambition is 10% of Saudi category value by 2032, with 2028 as the first full commercial year. The annual path and allocation between the models are proposed planning targets, not a validated sales forecast.
| Year | IONALYS | Nahdi own brand | Combined | Value USD m |
|---|---|---|---|---|
| 2028 / Y1 | 0.8% | 1.2% | 2.0% | 5.4 |
| 2029 / Y2 | 1.9% | 2.1% | 4.0% | 11.5 |
| 2030 / Y3 | 3.3% | 2.7% | 6.0% | 18.4 |
| 2031 / Y4 | 4.8% | 3.2% | 8.0% | 26.5 |
| 2032 / Y5 | 6.0% | 4.0% | 10.0% | 35.6 |
Each year’s illustrated value equals the publisher’s Saudi market forecast multiplied by the combined target share. It is not Nahdi net revenue or profit. Both models must use the same valuation basis; count each sale once.
Current competitor sales shares and Nahdi’s Saudi nasal-care share remain to be validated with local category data. Neither brand-usage surveys nor the total market forecast establish competitor sales shares.
Prices and margin rates remain to be agreed. Landed cost includes EXW supply price and agreed directly attributable inbound costs, applicable duty and non-recoverable charges. Recoverable VAT is excluded. Own-channel and external-wholesale economics must be assessed separately.
Five-year ambition & full assumptions ↑Cost definitions, channel economics & accounting sources ↑Proposed growth drivers ↑
IONALYS / Evidence appendix
Research & references.
Product-specific testing and selected publications on the wider water technology.
Product-specific sources
- Clinical / Preclinical summary
M. Richard Laboratories / P&B Group. CE marking for the ADW S-100® nasal spray.
Manufacturer release, 26 November 2025. References SPRA (10 October 2023) and the Epithelix MucilAir™ Pool nasal epithelial model (11 October 2024).
Read manufacturer release ↗ - In vitro / Nasal epithelium
Epithelix study extract supplied by the manufacturer.
Integrity, mucin and scratch-assay findings for the nasal epithelial model. The supplied slides are an excerpt, rather than the full study report.
View supplied extract (French) ↗ - Formulation / Preservation
Active ionised water: formulation safety and preservation summary.
Supplied manufacturer slides cite ISO 11930 challenge testing. The complete test report was not included in the supplied extract.
View supplied extract (French) ↗
Selected publications on the wider technology
These laboratory studies concern skin cells or virus inactivation. They are separate from the IONALYS human allergic-rhinitis trial.
- 2021 / Skin cells · In vitro
Yamamoto H, et al. Electrolytic-reduction ion water induces ceramide synthesis in human skin keratinocytes.
Drug Discoveries & Therapeutics. 2021;15(5):248–253. DOI: 10.5582/ddt.2021.01091.
Read publication ↗ - 2024 / Skin cells · In vitro
Yamamoto H, et al. Electrolytic-reduction ion water protects keratinocytes from hydrogen peroxide through radical scavenging activity and induction of AQP3 expression.
Drug Discoveries & Therapeutics. 2024;18(5):303–307. DOI: 10.5582/ddt.2024.01054.
Read publication ↗ - 2022 / Virus inactivation · In vitro
Wurtz N, Hasni I, Bancod A, La Scola B. Confirmatory Virucidal Activity of Ionised Active Water S-100® on the SARS-CoV-2 Virus.
Advances in Virology. 2022;5995775. DOI: 10.1155/2022/5995775. Laboratory findings; no IONALYS clinical antiviral indication is established by this study.
Read publication ↗